CompletedPHASE1, PHASE2NCT01090622
Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)
Studying Primary erythromelalgia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xenon Pharmaceuticals Inc.
- Principal Investigator
- Joost PH Drenth, MD PhDRadboud University Nijmegen Medical Center
- Intervention
- XPF-001(drug)
- Enrollment
- 4 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2010 – 2010
Study locations (1)
- Clinical Research Centre at Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01090622 on ClinicalTrials.govOther trials for Primary erythromelalgia
Additional recruiting or active studies for the same condition.